PHP
CLYM

Parkman Healthcare Partners’s Climb Bio CLYM Stock Holding History

Parkman Healthcare Partners’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.35M Buy
+563,484
New +$5.82M 0.75% 47
2025
Q1 		– Sell
-290,491
Closed -$523K – 106
2024
Q4 		$523K Buy
290,491
+11,716
+4% +$42.4K 0.07% 87
2024
Q3 		$1.42M Buy
+278,775
New +$1.97M 0.18% 83

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Parkman Healthcare Partners's CLYM Position: Q2 2026 in Review

Parkman Healthcare Partners opened a new position in Climb Bio (CLYM) in Q2 2026: 563,484 shares worth $7.35M. The stake represents 0.75% of the portfolio and ranks #47 among its holdings. This is a return to the name: Parkman Healthcare Partners previously reported a position in CLYM as recently as Q4 2024.

Parkman Healthcare Partners first reported a position in CLYM in Q3 2024 and has held it in 3 quarters since. 108 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Parkman Healthcare Partners held 563,484 shares of Climb Bio worth $7.35M as of Q2 2026.
  • Climb Bio was a new Parkman Healthcare Partners position in Q2 2026.
  • Climb Bio made up 0.75% of Parkman Healthcare Partners's portfolio in Q2 2026, its #47 holding.
  • Parkman Healthcare Partners first reported a position in Climb Bio in Q3 2024 and has held it in 3 quarters since.
  • 108 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Parkman Healthcare Partners's 13F filing for Q2 2026, filed 14 Aug 2026.